Drug or treatment
Girentuximab clinical trials
As of November 12, 2026, Find a Trial lists 4 clinical trials of Girentuximab that are recruiting, at sites in 4 countries (most in France (1), China (1), United States (1)). By phase: Phase 3 (2), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 4Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| 177Lu-TLX250 for advanced relapsed or recurrent clear-cell kidney cancer | Phase 3 | Sydney, New South Wales and 4 other locations | Recruiting | Sep 29, 2025 |
| 89Zr-TLX250 for imaging clear cell kidney cancer | Phase 3 | Beijing and 7 other locations | Recruiting | Dec 27, 2024 |
| PET/CT with zirconium‑labelled girentuximab to image CAIX in liver and gastro‑entero‑pancreatic neuroendocrine tumors | — | Nantes and 1 other locations | Recruiting | Dec 16, 2024 |
| Combination treatment for advanced clear cell kidney cancer | Phase 1/2 | Houston, Texas | Recruiting | Dec 23, 2022 |
All recruiting trials (4)
-
177Lu-TLX250 for advanced relapsed or recurrent clear-cell kidney cancer
This will test whether 177Lu-TLX250, a CAIX-targeting radioligand, helps adults with CAIX-positive advanced or relapsed clear-cell kidney cancer who have had 2–3 prior therapies.
-
89Zr-TLX250 for imaging clear cell kidney cancer
This study is testing a new imaging agent called 89Zr-TLX250 to see if it can help find clear cell kidney cancer in adults who have uncertain kidney masses before they have surgery.
-
PET/CT with zirconium‑labelled girentuximab to image CAIX in liver and gastro‑entero‑pancreatic neuroendocrine tumors
This will test whether a PET/CT scan using zirconium‑labelled girentuximab can find CAIX‑expressing hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and gastro‑entero‑pancreatic neuroendocrine tumors in adults.
-
Combination treatment for advanced clear cell kidney cancer
This study is testing a new combination of treatments for people with advanced clear cell kidney cancer to see if it is safe and effective.
Quick answers
How many clinical trials of Girentuximab are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in France (1 trial), China (1 trial), United States (1 trial), Australia (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 2, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.